Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-09-19

Clinical Trial Update: Exploratory Clinical Study of MT-2301 [Phase 2]

View source ↗

Summary

MT-2301 completed a Phase 2 exploratory study for Haemophilus influenzae type b infections; results were posted in September 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MT-2301

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Haemophilus Influenza Type b | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19